|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.42/-1.11
|
企業價值
183.17M
|
資產負債 |
每股賬面淨值
0.48
|
現金流量 |
現金流量率
--
|
損益表 |
收益
3.09M
|
每股收益
0.05
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/10/31 20:47 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S. |